Turning A "Brick Dust" Compound Into A Clinically Viable Oral Formulation

Developing oral formulations for poorly soluble, high-dose compounds requires overcoming severe bioavailability and physical stability barriers. Utilizing advanced wet milling technologies reduces active pharmaceutical ingredient particle sizes to the submicron range, vastly increasing surface area to accelerate dissolution and absorption. Careful optimization of surfactant and stabilizer concentrations prevents crystal growth and maintains long-term suspension consistency. These specialized particle engineering strategies successfully transform challenging molecules into clinically viable treatments, achieving significant improvements in systemic exposure without excessive excipient loads.

Read the full case study to explore the complete nanosuspension development framework.